Open an account

LifeMD

LFMD · NASDAQ

$2.25−$0.005 (−0.22%)TodayMarket closed ·
Prev close $2.25

LFMD analyst rating

BuyConsensus of 7 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy7
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 10 analysts

Average $8.29 (+269.2% upside)

Low
$5.05
Now
$2.25
High
$15.75

Upgrades and downgrades

The latest rating actions, newest first

LFMD analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Sep 17, 2026MaintainsBuy
HC Wainwright & Co.Aug 7, 2026MaintainsBuy
B. Riley SecuritiesAug 6, 2026MaintainsBuy
BTIGAug 6, 2026MaintainsBuy
HC Wainwright & Co.May 26, 2026MaintainsBuy
BTIGMay 4, 2026MaintainsBuy
MizuhoMar 16, 2026UpgradeNeutral → Outperform
Freedom BrokerMar 12, 2026MaintainsBuy
HC Wainwright & Co.Mar 11, 2026MaintainsBuy
BTIGMar 10, 2026MaintainsBuy

The case for and against

Updated Oct 21, 2026

Bull case

LifeMD is supported by a stronger distribution model, as the exclusive AT&T collaboration can funnel 29 million eligible customers into its platform without incremental acquisition cost and could begin contributing meaningfully to topline revenue in 4Q26. Its core weight management engine remains powerful, with about 108,000 subscribers at end-2Q26, roughly 95% of new patients starting branded GLP-1 therapy, and a jump in multi-month package selection from about 25% year to date before the pricing change to about 85% afterward, improving retention and lifetime value. Growth is also broadening beyond obesity through women’s health, where the patient base rose 134% sequentially, and the company’s expanding insurance and Medicare access, plus a pipeline of 30+ products by YE 2026, should support a longer-duration growth story.

Bear case

LifeMD is viewed negatively because its valuation depends on a relatively modest 2.0x EV/revenue multiple applied to projected sales per share of $4.51 for 3Q26 to 2Q27, implying limited upside if execution falters. Fundamental concerns center on slower-than-expected telehealth revenue growth, difficulty acquiring and retaining patients, and uncertainty around reaching profitability despite its integrated pharmacy, care center, and AI-enabled platform. The outlook is further pressured by intense competition and dilution risk, both of which could erode shareholder value even if the company maintains its direct-to-patient healthcare model.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.